Renal Anemia | Disease Landscape and Forecast | G7 | 2020
Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their limitations. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of such therapies as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). The renal anemia therapy market will expand over the 2019-2029 study period, fueled by increasing prevalence and demand for new drugs that can effectively, safely, and conveniently control the disease. The launches of several hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected during the study period; of this drug class, roxadustat was the first to launch (in Japan in 2019). Although these new therapies offer advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.
QUESTIONS ANSWERED
- What opportunities exist for the marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
- Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors given the CV issues associated with current therapies?
- With the availability of biosimilars in the United States, will emerging therapies offering only incremental improvements over existing therapies struggle?
